Toronto Memory Program is a multidisciplinary, community based, medical facility specializing in the Study medication is provided to you free of charge.
(13)
Every individual treated in our clinic receives the best medical care available. This care is delivered by a knowledgeable and compassionate team in a relaxed and supportive setting. Treatment focuses on the well-being of both our patients and their families. We optimize the use of currently available pharmacological and non-pharmacological interventions and support patients and families through e
ach stage of the disease. We have participated in over 100 international trials in Alzheimer's disease. We assist in the development of pharmaceuticals that hold promise to improve symptoms and/or alter the course of this disease. All studies are conducted according to national and international regulations and codes of conduct, and are approved by independent research ethic boards. Toronto Memory Program has been Health Canada inspected with no findings. Participation in research is voluntary and there are no fees to participate.
Last week, Toronto Memory Program hosted a heartwarming Appreciation Dinner for the incredible participants and families of the Eli Lilly A4 Study. Your dedication fuels our mission to conquer Alzheimer's disease. Thank you for being the driving force of progress!
Meet Tyson Haller, a determined individual who turned his concern over forgetfulness into action. With a family history of Alzheimer's, he joined Toronto Memory Program's groundbreaking study in 2020. Now 59, he's part of the AHEAD study, testing a drug to prevent symptomatic Alzheimer's. Every 2 weeks, he invests 90 minutes to make a difference, believing in the power of research for society's future.
When Tyson Haller reached his 50s, he began to notice he wasn’t so sharp at remembering names. “Very mildly, I would forget (a friend’s) wife’s name, and I’d go, ‘But
Meet Tyson Haller, a determined individual who turned his concern over forgetfulness into action. With a family history of Alzheimer's, he joined Toronto Memory Program's groundbreaking study in 2020. Now 59, he's part of the AHEAD study, testing a drug to prevent symptomatic Alzheimer's. Every 2 weeks, he invests 90 minutes to make a difference, believing in the power of research for society's future.
https://www.toronto.com/news/north-york-medical-clinic-tests-drug-to-prevent-alzheimers-disease/article_e6e56d17-d151-5b7c-a36f-f383ed683f4c.html?
When Tyson Haller reached his 50s, he began to notice he wasn’t so sharp at remembering names. “Very mildly, I would forget (a friend’s) wife’s name, and I’d go, ‘But
Join Dr. Ian Cohen, President and Research Physician at Toronto Memory Program, as he breaks down the stages of Alzheimer's disease in this informative video.
Discover the fascinating insights Dr. Sharon Cohen shared about the revolutionary use of AI for early Alzheimer's detection!
The relentless pursuit of detecting Alzheimer's has posed a grueling battle for families and the medical community, but a simple eye scan may help ease that burden.
Don't miss this eye-opening interview with Dr. Sharon Cohen on Curiouscast podcast. Listen now to gain invaluable insights into Alzheimer's detection through the eyes!
Show Shaye Ganam, Ep Signs of Alzheimer’s may be detected in your eyes, and this AI scan could help find it - 24 Jul 2023
These results come in large part due to the participation of individuals at Toronto Memory Program where the first human dose of this potential new treatment was given. Congratulations to Alnylam Pharmaceuticals on positive results.
These results come in large part due to the participation of individuals at Toronto Memory Program where the first human dose of this potential new treatment…
FDA Approves New Breakthrough Drug for Alzheimer's Treatment!
Join us in celebrating this historic moment and to thank those who helped us get here - Dr. Sharon Cohen, the amazing clinical trial participants and their families, and the research professionals who played a vital role in bringing this life-changing drug to the market.
This remarkable milestone brings hope and promises a brighter future for millions affected by Alzheimer's disease.
The US Food and Drug Administration on Thursday granted full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the disease.
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.
Read the full article to learn more about this exciting breakthrough in Alzheimer's research.
The Investor Relations website contains information about Cassava Sciences, Inc.'s business for stockholders, potential investors, and financial analysts.
Check out this insightful presentation by Dr. Ian Cohen and Justine Reaume on empowering pharmacists to support Alzheimer's patients through clinical trials! 💊
Dive deeper into the groundbreaking AHEAD study for Alzheimer's disease prevention with Dr. Sharon Cohen!
Help us get AHEAD of Alzheimer's disease. Join a trial that aims to help prevent Alzheimer’s disease by testing an investigational treatment aimed at delayin...
Watch to learn more about the Biogen ENVISION study of aducanumab, featuring Dr. Ian Cohen and Lindsay Snow.
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (ENVISION)
An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer’s drug shows “clinical benefit” for the treatment of the disease, paving the way for the medication to be considered for full FDA approval. A decision from the FDA is expected by July 6.
An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer’s drug lecanemab shows “clinical benefit” for the treatment of the disease, paving the way for the medication to be considered for full FDA approval, which is expected by July 6.
Participation in Alzheimer's disease clinical trials is surrounded by misconceptions. It's time to debunk these myths!
Dr. Sharon Cohen, a beacon of hope in the fight against Alzheimer's disease, shares groundbreaking insights in this captivating interview with CBC Fresh Air.
When it comes to Alzheimer's there is no cure; prevention and treatment are the only options. There is a study happening right now might change that. Dr. Sharon Cohen is Medical Director with the Toronto Memory Program. She joined us to tell us about the drug they're testing.
Leading expert, Dr. Sharon Cohen, shares insights on groundbreaking Alzheimer's drugs and essential prevention methods in exclusive interview.
For years, people who were concerned about forgetfulness, senior moments and possible mild...
Are you passionate about making a real difference in the lives of those affected by Alzheimer's disease? We have an incredible opportunity for you to play a crucial role in the battle against this devastating condition.
Learn how to participate in the AHEAD Study, an Alzheimer's disease clinical trial testing if intervening AHEAD of symptoms can prevent future memory loss and dementia.
Dr. Sharon Cohen at the Walk for Alzheimer’s this weekend.
A beautiful day to participate in the Walk for Alzheimer’s!
We all forget things from time to time and this can become more frequent as we get older. However, sometimes a person may experience cognitive changes that are not expected for someone their age.
To learn more about Mild Cognitive Impairment clinical trials, please visit: https://lnkd.in/gFHjQ7dB
Tomorrow is International Clinical Trials Day!
In 2005, International Clinical Trials Day was launched to commemorate the day when James Lind started the clinical trial on May 20, 1747.
This day serves as an opportunity to recognize the vital role that our team plays in advancing Alzheimer's disease research.
By participating in Alzheimer's disease research, you can help accelerate progress and build toward a world without Alzheimer's disease.
Research is getting us closer every day to finding the cause and cures for Alzheimer's disease.
Visit our website to learn more about Alzheimer's disease research opportunities: https://lnkd.in/gFHjQ7dB
Eli Lilly and Company announced the positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease.
Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year. Donanemab treatment slowed clinical decline by 35% compared to placebo, and resulted in 40% less decline on the ability to perform activities of daily living.
We are incredibly grateful to our participants in the TRAILBLAZER-ALZ 2 study!
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Worried about your or a loved one’s memory? The AHEAD Study needs research heroes to help find a treatment to slow memory loss. Find more information about the AHEAD Study at https://www.aheadstudy.org/
We are pleased to announce that Toronto Memory Program randomized the first Canadian participant in Biogen's ENVISION study of aducanumab! 🍁
Will you help shape the treatments of tomorrow? Every clinical trial needs people just like you!
My son was diagnosed with stage IV neuroblastoma cancer at 2 years of age and over his entire 5 years of treatment, he was always enrolled in a clinical trial. Clinical trials meant that he had access to the best treatment and the highest level of care. They gave us hope and saved his life, for whic...
Receiving an Alzheimer's disease diagnosis is a life changing moment for the person living with it and for all those who love them. In this personal firsthand account, Ruby Qureshi, a research participant at Toronto Memory Program, takes us on that journey.
Receiving an Alzheimer's disease diagnosis is a life changing moment for the person living with it and for all those who love them. In this very personal firsthand account Ruby Qureshi takes us on that journey. She talks about being diagnosed, living with Alzheimer's, and dispels some of the myths a
Dr. Sharon Cohen will be one of the speakers at the next edition of Dementia Talks! Canada, presented by the Alzheimer Society of Canada and Brain Canada.
On April 19th, don't miss our talk titled “New dementia drugs and therapies: What Canadians should know.”
To find out more and to register, visit alzheimer.ca/apriltalk
Dr. Sharon Cohen will be one of the speakers at the next edition of Dementia Talks! Canada, presented by the Alzheimer Society of Canada and Brain Canada.
On April 19th, don't miss our talk titled “New dementia drugs and therapies: What Canadians should know.”
To find out more and to register, visit alzheimer.ca/apriltalk
Join us April 19 at 12 p.m. Eastern Time for an expert chat to learn about new types of drugs and therapies now in development for dementia. This event is part of the Dementia Talks! Canada series.
CELIA seeks to recruit about 735 adults, ages 50-80, with mild cognitive impairment or mild dementia due to Alzheimer’s who haven’t received any other treatment for the disease.
New PET data from the Phase 1b extension study showed tau aggregation was reduced across all tested Alzheimer's patients brain regions.
Taking a daily slow-breathing exercise for a month lowered the amount of beta-amyloid in the blood.
Take a Deep Breath—It Just Might Lower Your Risk for Alzheimer’s Quick Links Article Comments References Further Reading Tools Add to my Library Follow Comments Share How would you like to share? Facebook Twitter LinkedIn Back to the Top 25 Mar 2023 Lifestyle changes have been touted as a way to...
On Jan 24, 2023, Cassava Sciences announced the top-line results of a phase 2 clinical trial of Simufilam, an investigational oral drug for Alzheimer’s disease. In this single-arm, open-label safety study, Simufilam demonstrated good safety and tolerability. In terms of the exploratory efficacy endpoint, 47% of treated patients had a 4.7-point improvement from baseline on the ADAS-Cog score, which assesses cognitive decline, after 1 year of treatment. The company has initiated Phase 3 clinical trials to evaluate the effect of Simufilam in patients with mild to moderate Alzheimer’s disease.
47% of treated Alzheimer's patients had a 4.7-point improvement from baseline on the ADAS-Cog score, which assesses cognitive decline, after 1 year of treatment.
We are pleased to announce that Toronto Memory Program screened the first Canadian participant in Biogen's CELIA study! To learn more about our research opportunities, visit: https://torontomemoryprogram.com/studies/
If you are interested in participating in one of our studies or simply looking for information regarding our programs, click on the link below to find out more information.
Dr. Sanjay Gupta is reinvesting in his brain, not simply to stave off decline, but to make his next phase of life the best it can be. Here's why the advancements we've made in science can make this a goal everyone can tackle, too.
Toronto Memory Program is proud to have screened the first Canadian participant in Biogen's ENVISION study of today.
A HUGE thank you provided to our clinical trial participants and their contribution to research and to the generation of new knowledge.
Dr. Sharon Cohen of the Toronto Memory Program provided perspective on the steps the general public can take toward reducing the risk of Alzheimer disease and initiating treatment early when needed.
The behavioral neurologist and medical director of the Toronto Memory Program provided perspective on the steps the general public can take toward reducing the risk of Alzheimer disease and initiating treatment early when needed. [WATCH TIME: 4 minutes]
January is Alzheimer's Awareness Month in Canada. During this month we encourage you to learn more about clinical trials. Without clinical research and the help of participants, there can be no treatments, prevention, or cure for Alzheimer's disease.
To learn more, please contact our Clinical Trial Education Team at 416-386-9606 or [email protected].
Breakthrough!
FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment
The FDA approved Leqembi (lecanemab-irmb), the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiol
Happy holidays from Toronto Memory Program! May your holidays be full of warmth and cheer.
Our office will be closed on Dec 26, Dec 27, and Jan 2.
1 Valleybrook Drive, Suite 400
Toronto, ON
M3B2S7
| Monday | 8am - 4pm |
| Tuesday | 8am - 4pm |
| Wednesday | 8am - 4pm |
| Thursday | 8am - 4pm |
| Friday | 8am - 4pm |
Be the first to know and let us send you an email when Toronto Memory Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to Toronto Memory Program:
The AHEAD Study tests whether an investigational treatment aimed at removing amyloid from the brain can also slow the earliest memory changes in people with a higher risk of developing Alzheimer’s disease. Help us get AHEAD of Alzheimer’s disease. We need healthy adults ages 55–80 to participate in the AHEAD Study. To learn more: https://www.aheadstudy.org/
In this video, we uncover ALZ-801 (valiltramiprosate), the first potential disease-modifying oral treatment for patients with Alzheimer’s disease. To learn more: [email protected]
Dr. Sharon Cohen discuss the FDA approval of Aduhelm, the importance of this decision for the Alzhiemer's community and what's next for future treatment options. CTV News #Alzheimers
The FDA approves the first Alzheimer's drug since 2003. Meet Wendy Atkinson who is a participant in this clinical research trial and the importance of this approval for the Alzheimer’s disease community. Dr. Sharon Cohen gives us a breakdown of the drug, Aducanumab. #endalz #alzheimers #clinicalresearch
It’s Clinical Trials Day! At Toronto Memory Program, we are passionate individuals who care about making sure new and cutting-edge clinical trials are brought to our local communities. This allows those who struggle with traditional treatment options to have an opportunity to explore new treatment options. We can’t do this alone and that’s why we need your help! With research anything is possible so let’s discover a better tomorrow, together! #clinicalresearch #clinicaltrialsday #weareallinthistogether #ourreason #weriseforresearch
Toronto Memory Program is enrolling for the Phase 3 Green Memory Study assessing GV-971 (oligomannate), a purified extract of brown algae, in mild to moderate Alzheimer’s disease. GV-971 was approved in China in 2019 for symptomatic treatment of Alzheimer’s disease based on positive phase 3 results showing earlier, more substantial, and longer duration of symptom benefit than that associated with approved memory medications. It is the first new drug to be approved for Alzheimer’s disease in 17 years and has an outstanding safety profile. To learn more about the trial or to see if you qualify, please call one of our Clinical Trial Educators at 416-386-9606.
Toronto Memory Program's new RetiSpec Retinal scan Study was featured by CTV's Pauline Chan @TOYourHealth9 on August 5, 2019. @RetiSpec could be a future alternative to #amyloid PET scans or spinal taps to detect early signs of #Alzheimer's disease.
Dr. Sharon Cohen, medical director of Toronto Memory Program, discusses updates from the 2019 Alzheimer’s Association International Conference with host, Bob Komsic, on Zoomer Radio’s “Week in Review", Sunday, July 21, 2019.
Dr. Sharon Cohen on GlobalTV discussing what family members night see in their parents, over the holidays, that might suggest Alzheimer's disease.
This story, broadcast on CTV Toronto News at 6 on Friday 12/14/2018, previews Steve McNeil's annual 19-hour and 26-minute non-stop skate-a-thon, with proceeds going to Alzheimer Society Toronto. Toronto Memory Program is a corporate sponsor of the event.
A pioneering astronaut, the wife and daughter of a rock star and a well-known hockey referee fundraiser, paid a visit to Toronto Memory Program. They found common ground with Toronto Memory Program's Drs. Sharon and Ian Cohen, to raise awareness about clinical trials and the search for an Alzheimer's disease cure.
Dr. Sharon Cohen speaks with Cheri Preston of ABC News Radio about new research drugs to slow down Alzheimer’s progression.
Dr. Sharon Cohen captured by CTV Barrie News presenting to a sold out audience at the Third Age Barrie seminar on Alzheimer's prevention. They really came through. Over 100 people consented to participate in pre-screening for the Generation I global Alzhiemer's prevention trial taking place Toronto Memory Program.
Dr. Sharon Cohen on CTV with Marcia Macmillan discussing the new CIHI report on dementia in Canada. Caregivers continue to deal with significant distress and need more support. Make sure your politicians keep this disease in mind when allocating resources.
Make sure not to miss Dr. Sharon Cohen on Zoomer Radio AM740 Sunday April 8th at noon as she talks about Alzheimer's disease prevention trials. Here is a short clip to entice you!
Dr. Sharon Cohen of Toronto Memory program is featured on NewsTalk 1010’s “The Night Side with Barb DiGiulio” on Thursday, March 29, 2018. The topic: would you take a 60-minute test to determine a potential genetic link to Alzheimer’s, and be enrolled in a clinical trial aimed at fighting disease years before any symptoms? Thanks to host Barb DiGiulio for presenting this question to her audience. torontomemoryprogram.com (416) 386-9761
Call us at 416-386-9606 and speak to our clinical trial educator for more details.
Dr. Sharon Cohen leads the shoelace tying ceremony in the #WalkForMemories 2017. She reminds us to continue to spread awareness and increase volunteerism in fighting against Alzheimer's disease.
These are the people behind clinical trials. We had the pleasure of working on this project to help showcase a patient's experience in an Alzheimer's research trial. A special thank you to Mrs. & Mr. Lompart for sharing their story.
"The A4 Study is a landmark clinical trial to prevent the memory loss associated with Alzheimer's disease"
"EMDA Israeli Alzheimer Association: The wrong movie" An amazing and powerful video. Some insight into what victims of Alzheimer's disease have to endure nearly every day.
Employment & Disability Law - Serving Ontario
Duncan Mill RoadBluesky Best Health Care Products
Duncan Mill Road
Elizabeth Grant International Inc.
Kennedy Road
Caprice Boisvert: Movement Re-education
Dupont Street
#}
